| Literature DB >> 36249323 |
Deepank S Gupta1, Sonali S Bharate1.
Abstract
Niclosamide is a well-known broad-spectrum antiparasitic drug used for human as well as veterinary tapeworm infections. Recently, it attracted attention as an antiviral agent for treating coronavirus disease 2019. It is administered orally in humans to treat tapeworm infections. Furthermore, it is a registered pesticide and molluscicide to control infections in the aquaculture industry. Its chronic environmental exposure has potential toxicities when such contaminated seafood is consumed. Therefore, monitoring its residual concentration in food products (seafood, water, water waste, etc.) and pharmaceuticals (active pharmaceutical ingredients, bulk drugs, and formulations) is imperative. The present review critically investigates the sophisticated techniques employed for analyzing niclosamide, its degradation products, and metabolites in various samples and matrices. The future scope for green analytical methods, green sample extraction and preparation is also deliberated.Entities:
Keywords: analytical techniques; antiviral; clinical application; niclosamide; pesticide
Year: 2022 PMID: 36249323 PMCID: PMC9538213 DOI: 10.1002/sscp.202200097
Source DB: PubMed Journal: Sep Sci Plus ISSN: 2573-1815
FIGURE 1Roadmap of the current development status of niclosamide.
FIGURE 2Overview of analytical methods and matrices for niclosamide analysis
FIGURE 3Metabolites and degradation products of niclosamide
Chromatographic methods for estimation of niclosamide in formulations and biological samples
| Sr. No. | Sample | Method details | Sample extraction | Detector | Linearity range | LOQ | LOD | Reference |
|---|---|---|---|---|---|---|---|---|
| 1 | Degradation products |
Kinetex XB‐C18 column (75 × 4.6 mm × 2.6 μm); column temp. of 35°C Mobile phase: Water (Phase A) and Methanol (Phase B), all containing 0.2% formic acid (v/v) with a flow rate of 0.5 ml/min Gradient elution: Time, A:B (%v/v) = 0→1 min, 90:10; 6→8 min, 20:80; 8.5→10.5 min, 10:90; 11→13 min, 90:10. | NA | DAD (330 nm) and 6410 quadrupole tandem mass spectrometer |
Niclosamide: 1–100 ng/ml 2‐chloro‐4‐nitroaniline: 50–2200 ng/ml Aminoniclosamide: 2–2500 ng/ml; Hydroxyniclosamide: 2–300 ng/ml; 5‐chlorosalicylic acid: 5–1000 ng/ml | 0.1 ng/ml | NA | [ |
| 2 | Degradation products from pharmaceutical tablets |
Shimpack column VPODS (25 × 4.6 mm) Mobile phase: methanol: water (70:30 v/v) at 1 ml/min | NA | UV detection at 320 nm | NA | NA | NA | [ |
| 3 | Residue analysis in water, soil, and rice samples |
UPLC BEH C18 column (50 mm × 2.1 mm, 1.7 μm), maintained at 30°C. Mobile phase: A, water and B, methanol at 0.3 ml/min Gradient elution: Time (min)/ A (%)/ B (%) = 0/90/10; 1.5/10/90; 3.5/10/90; 3.6/90/10; 5/90/10. | ACN | MS/MS | 0.005–0.05 mg/kg | 5 μg/kg | 0.01 μg/kg | [ |
| 4 | Aquatic animal tissue |
Thermo Hypersil BDS octadecylsilane column (150 mm × 2.1 mm, 5 μm) at 35°C. Mobile phase: A, ACN, and B, water at a rate of 0.2 ml/min Gradient elution: 0–2 min, 50% A; 2–2.5 min, 50%→90% A; 2.5–7 min, 90% A, 7–7.1 min, 90%→50% A; 7.1–8 min, 50% A | Ammoniated ACN | ESI‐MS‐MS | 0.5–100 μg/kg | 0.5 μg/kg | 0.2 μg/kg | [ |
| 5 | Bulk API |
Hibar C18 column (250 mm × 4.66 mm, 5 μm) Mobile phase: MeOH: (NH4)3PO4 buffer (85:15 v/v) with pH adjusted to 5.47 with a flow rate of 1.2 ml/min | MeOH | PDA at 332 nm | 0.01–100 μg/ml | 0.01 μg/ml | 0.0048 μg/ml | [ |
| 6 | Degradation products |
Fortis C18 column (150 × 4.6 mm, 5 μm) at 25°C Mobile phase: 0.1% formic acid and ACN at 1 ml/min Gradient elution: 0‐6 min, 45% ACN; 6–8 min, 45%–90% ACN, 10–12 min, 45% ACN | NA | PDA at 334 nm | 30–70 μg/ml | 0.06 μg/ml | 0.02 μg/ml | [ |
| 7 | Tablets |
Zorbax C18 (250 × 4.6, 5 μm) column at 30°C Mobile phase: KH2PO4: ACN (60:40 v/v) at 1 ml/min | MeOH | PDA at 290 nm | NA | NA | NA | [ |
| 8 | Veterinary formulations |
Luna C‐18 (5 μm × 25 cm) column Mobile phase: ACN: buffer solutions (2:8, v/v) at 0.8 ml/min Buffer solution A: 0.005 M Na hexanesulphonic acid and glacial acetic acid (8 ml) and adjust the pH to 3 by phosphoric acid Buffer solution B: 0.01 M dibutylamine and adjust to pH 3 with phosphoric acid |
| PDA at 240 nm | 10–180 μg/ml | NA | NA | [ |
| 9 | Food analysis (fish sample) |
Phenomenex Prodigy ODS reverse phase column (150 mm × 4.6 mm, 5 μm) Mobile phase: A, 58 mM sodium acetate buffer and B, ACN at 1 ml/min Gradient elution: 0–5 min, 35% A; 5–10 min, 50% A; 10–20 min, 60% A; 20–25 min, 80% A; 25–30 min, 100% A | Acetone extractions with clean‐up on SPE | PDA at 360 and 335 nm | NA | NA | 0.0107 μg/g | [ |
| 10 | Pharmaceutical suspension |
Phenomenex L1 HPLC analytical C18 100 A0 column (250 × 4.6 mm, 5 μ) Mobile phase: KH2PO4 buffer + ACN (70:30 v/v) at 1.0 ml/min | 0.1 N methanolic HCl | UV detection at 290 nm | 80–130 μg/ml | 9.936 μg/ml | 5.673 μg/ml | [ |
| 11 | Forensic investigations |
Acclaim 120‐C18 column (150 mm × 3 mm, 3 μm) at 30°C Mobile phase: A, 20 mmol/L ammonium acetate of pH 4.5 and B, MeOH at 0.3 ml/min Gradient elution: 0–4 min, 85% B; 4–13 min, 85%→90% B; 13–14 min, 90% B; 14–15 min, 90%→85% B; 15–19 min, 85% B | DCM: MeOH (4:1 v/v) | MS‐MS | 0.04–2 ng/ml | NA | 0.02 ng/ml | [ |
FIGURE 4Sample extraction and preparation for analyzing niclosamide from aquatic tissues [30]